Pramodini Medicare
OPENIPO Date: 12 Aug - 14 Aug 2026
Listing Date: 19 Aug 2026
Price Range
₹110 to ₹118
Issue Size
69 Cr
Min Investment
₹1,32,000
Lot Size
1200 Shares
Schedule of Pramodini Medicare
Issue open date
12 Aug 2026
Issue close date
14 Aug 2026
UPI mandate deadline
14 Aug 2026 (5 PM)
Allotment finalization
17 Aug 2026
Share credit
18 Aug 2026
Listing date
19 Aug 2026
Mandate end date
29 Aug 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 69 Cr |
| Fresh Issue | 0.54 Cr |
| Offer for Sale | 0.05 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 17 Aug 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 12 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 11 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 10 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 9 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 8 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 7 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 6 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 5 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
| 4 Aug 2026 | ₹118 | ₹0 | ₹118 (0%) |
Performance Pramodini Medicare
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹110 to ₹118 | .... | .... | .... |
About Pramodini Medicare
Pramodini Medicare Limited is a Vijayawada-based Indian healthcare diagnostics company providing technology-enabled diagnostic services across radiology, clinical laboratory testing and nuclear medicine. Its services include MRI, CT, ultrasound, pathology, microbiology, immunology, PET-CT and nuclear therapy, along with 24×7 teleradiology. The company serves government and private hospitals, PSUs and medical colleges across Tier I, II and III cities. Its business operates through PPP, private partnerships, PSU alliances and standalone diagnostic centres, giving it multiple channels for expansion. The company was incorporated in 2000 as Pramodini Medicare Private Limited and converted into a public limited company in 2025.
| Founded in | 2000 |
| Managing director | Dr. Chalasani Kuldeep Kumar |
| Parent organization |
Financial Overview
Strengths
- Diversified diagnostic portfolio: Presence across radiology, pathology/clinical laboratory and nuclear medicine reduces dependence on a single diagnostic segment.
- Multiple business models: PPPs, private partnerships, PSU alliances and standalone centres provide diversified customer acquisition and revenue opportunities.
- Technology-enabled services: MRI, CT, PET-CT and 24×7 teleradiology allow the company to provide specialized diagnostics beyond conventional pathology testing.
- Long operating track record: More than two decades of operations and presence across different city tiers provide established healthcare-sector experience.
Risks
- High capital intensity: Advanced diagnostic equipment such as MRI, CT and PET-CT requires significant capital expenditure, maintenance and periodic replacement.
- Debt/financial leverage risk: Publicly available records show substantial outstanding/open charges, including charges involving Axis Bank and other lenders, indicating reliance on external financing.
- Competition: The company operates in a competitive diagnostics market with established national chains, regional diagnostic providers and hospital-based laboratories.
- PPP and institutional dependency: A meaningful part of the business model involves government hospitals, PSUs and institutional partnerships, making contract renewals, tender outcomes and government spending important to future growth.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 1.81 |
| Non-Institutional Investors (NIIs) | 0.23 |
| Retail Individual Investors (RIIs) | 0.39 |
| Employee | N/A |
| Total | 0.75 |